OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Angelo Antonini, Victor S.C. Fung, James T. Boyd, et al.
Movement Disorders (2016) Vol. 31, Iss. 4, pp. 530-537
Open Access | Times Cited: 81
Showing 1-25 of 81 citing articles:
Parkinson disease
Werner Poewe, Klaus Seppi, Caroline M. Tanner, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 3800
Werner Poewe, Klaus Seppi, Caroline M. Tanner, et al.
Nature Reviews Disease Primers (2017) Vol. 3, Iss. 1
Closed Access | Times Cited: 3800
International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease
Susan H. Fox, Regina Katzenschlager, Shen‐Yang Lim, et al.
Movement Disorders (2018) Vol. 33, Iss. 8, pp. 1248-1266
Closed Access | Times Cited: 790
Susan H. Fox, Regina Katzenschlager, Shen‐Yang Lim, et al.
Movement Disorders (2018) Vol. 33, Iss. 8, pp. 1248-1266
Closed Access | Times Cited: 790
Levodopa‐induced dyskinesia in Parkinson disease: Current and evolving concepts
Alberto J. Espay, Francesca Morgante, Aristide Merola, et al.
Annals of Neurology (2018) Vol. 84, Iss. 6, pp. 797-811
Open Access | Times Cited: 283
Alberto J. Espay, Francesca Morgante, Aristide Merola, et al.
Annals of Neurology (2018) Vol. 84, Iss. 6, pp. 797-811
Open Access | Times Cited: 283
Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry
Angelo Antonini, Werner Poewe, К. Ray Chaudhuri, et al.
Parkinsonism & Related Disorders (2017) Vol. 45, pp. 13-20
Open Access | Times Cited: 179
Angelo Antonini, Werner Poewe, К. Ray Chaudhuri, et al.
Parkinsonism & Related Disorders (2017) Vol. 45, pp. 13-20
Open Access | Times Cited: 179
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial
Michael J. Soileau, Jason Aldred, Kumar Budur, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 12, pp. 1099-1109
Closed Access | Times Cited: 87
Michael J. Soileau, Jason Aldred, Kumar Budur, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 12, pp. 1099-1109
Closed Access | Times Cited: 87
Medical and surgical management of advanced Parkinson's disease
Angelo Antonini, Elena Moro, Clécio Godeiro‐Júnior, et al.
Movement Disorders (2018) Vol. 33, Iss. 6, pp. 900-908
Closed Access | Times Cited: 161
Angelo Antonini, Elena Moro, Clécio Godeiro‐Júnior, et al.
Movement Disorders (2018) Vol. 33, Iss. 6, pp. 900-908
Closed Access | Times Cited: 161
Levodopa-induced dyskinesia: clinical features, incidence, and risk factors
Tai Ngoc Tran, Trang N. N. Vo, Karen Frei, et al.
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1109-1117
Closed Access | Times Cited: 119
Tai Ngoc Tran, Trang N. N. Vo, Karen Frei, et al.
Journal of Neural Transmission (2018) Vol. 125, Iss. 8, pp. 1109-1117
Closed Access | Times Cited: 119
Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l -DOPA delivery in the 6-OHDA model of Parkinson's disease
Giovanna Mulas, Elena Espa, Sandro Fenu, et al.
Experimental Neurology (2016) Vol. 286, pp. 83-92
Closed Access | Times Cited: 89
Giovanna Mulas, Elena Espa, Sandro Fenu, et al.
Experimental Neurology (2016) Vol. 286, pp. 83-92
Closed Access | Times Cited: 89
Medical Management and Prevention of Motor Complications in Parkinson's Disease
Stephen Aradi, Robert A. Hauser
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1339-1365
Open Access | Times Cited: 80
Stephen Aradi, Robert A. Hauser
Neurotherapeutics (2020) Vol. 17, Iss. 4, pp. 1339-1365
Open Access | Times Cited: 80
Clinical benefit of MAO-B and COMT inhibition in Parkinson’s disease: practical considerations
Martin Regensburger, Chi Wang Ip, Zacharias Kohl, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 847-861
Open Access | Times Cited: 31
Martin Regensburger, Chi Wang Ip, Zacharias Kohl, et al.
Journal of Neural Transmission (2023) Vol. 130, Iss. 6, pp. 847-861
Open Access | Times Cited: 31
Translational molecular imaging and drug development in Parkinson’s disease
Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawoud, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
Ahmed Haider, Nehal H. Elghazawy, Alyaa Dawoud, et al.
Molecular Neurodegeneration (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 30
Dopamine dynamics are dispensable for movement but promote reward responses
Xintong Cai, Changliang Liu, Iku Tsutsui‐Kimura, et al.
Nature (2024) Vol. 635, Iss. 8038, pp. 406-414
Closed Access | Times Cited: 11
Xintong Cai, Changliang Liu, Iku Tsutsui‐Kimura, et al.
Nature (2024) Vol. 635, Iss. 8038, pp. 406-414
Closed Access | Times Cited: 11
Motor and non-motor outcomes in patients with advanced Parkinson’s disease treated with levodopa/carbidopa intestinal gel: final results of the GREENFIELD observational study
Leonardo Lopiano, Nicola Modugno, Pietro Marano, et al.
Journal of Neurology (2019) Vol. 266, Iss. 9, pp. 2164-2176
Open Access | Times Cited: 55
Leonardo Lopiano, Nicola Modugno, Pietro Marano, et al.
Journal of Neurology (2019) Vol. 266, Iss. 9, pp. 2164-2176
Open Access | Times Cited: 55
Levodopa Carbidopa Intestinal Gel in Advanced Parkinson’s Disease: DUOGLOBE Final 3-Year Results
К. Ray Chaudhuri, Norbert Kovács, Francesco E. Pontieri, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 5, pp. 769-783
Open Access | Times Cited: 17
К. Ray Chaudhuri, Norbert Kovács, Francesco E. Pontieri, et al.
Journal of Parkinson s Disease (2023) Vol. 13, Iss. 5, pp. 769-783
Open Access | Times Cited: 17
Common Myths in the Use of Levodopa in Parkinson Disease
Alberto J. Espay, Anthony E. Lang
JAMA Neurology (2017) Vol. 74, Iss. 6, pp. 633-633
Closed Access | Times Cited: 58
Alberto J. Espay, Anthony E. Lang
JAMA Neurology (2017) Vol. 74, Iss. 6, pp. 633-633
Closed Access | Times Cited: 58
Algorithms for the treatment of motor problems in Parkinson's disease
Espen Dietrichs, Per Odin
Acta Neurologica Scandinavica (2017) Vol. 136, Iss. 5, pp. 378-385
Open Access | Times Cited: 54
Espen Dietrichs, Per Odin
Acta Neurologica Scandinavica (2017) Vol. 136, Iss. 5, pp. 378-385
Open Access | Times Cited: 54
Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up
Mariachiara Sensi, Giovanni Cossu, Francesca Mancini, et al.
Parkinsonism & Related Disorders (2017) Vol. 38, pp. 90-92
Open Access | Times Cited: 51
Mariachiara Sensi, Giovanni Cossu, Francesca Mancini, et al.
Parkinsonism & Related Disorders (2017) Vol. 38, pp. 90-92
Open Access | Times Cited: 51
Dyskinesia Matters
M. Angela Cenci, Sara Riggare, Rajesh Pahwa, et al.
Movement Disorders (2019) Vol. 35, Iss. 3, pp. 392-396
Closed Access | Times Cited: 47
M. Angela Cenci, Sara Riggare, Rajesh Pahwa, et al.
Movement Disorders (2019) Vol. 35, Iss. 3, pp. 392-396
Closed Access | Times Cited: 47
A Stage-Based Approach to Therapy in Parkinson’s Disease
Claudia Carrarini, Mirella Russo, Fedele Dono, et al.
Biomolecules (2019) Vol. 9, Iss. 8, pp. 388-388
Open Access | Times Cited: 46
Claudia Carrarini, Mirella Russo, Fedele Dono, et al.
Biomolecules (2019) Vol. 9, Iss. 8, pp. 388-388
Open Access | Times Cited: 46
Should there be less emphasis on levodopa‐induced dyskinesia in Parkinson's disease?
К. Ray Chaudhuri, Peter Jenner, Angelo Antonini
Movement Disorders (2019) Vol. 34, Iss. 6, pp. 816-819
Closed Access | Times Cited: 43
К. Ray Chaudhuri, Peter Jenner, Angelo Antonini
Movement Disorders (2019) Vol. 34, Iss. 6, pp. 816-819
Closed Access | Times Cited: 43
Pathophysiological Mechanisms and Experimental Pharmacotherapy for L-Dopa-Induced Dyskinesia
A Fabbrini, Andrea Guerra
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 469-485
Open Access | Times Cited: 37
A Fabbrini, Andrea Guerra
Journal of Experimental Pharmacology (2021) Vol. Volume 13, pp. 469-485
Open Access | Times Cited: 37
Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
Libo Wang, Jia Li, Jiajun Chen
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 40
Libo Wang, Jia Li, Jiajun Chen
Frontiers in Neurology (2018) Vol. 9
Open Access | Times Cited: 40
Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson’s Disease
Mark D. Latt, Simon J.G. Lewis, Olfat Zekry, et al.
Drugs & Aging (2019) Vol. 36, Iss. 3, pp. 189-202
Closed Access | Times Cited: 38
Mark D. Latt, Simon J.G. Lewis, Olfat Zekry, et al.
Drugs & Aging (2019) Vol. 36, Iss. 3, pp. 189-202
Closed Access | Times Cited: 38
Translating Evidence to Advanced Parkinson's Disease Patients: A Systematic Review and Meta‐Analysis
F. Nijhuis, Rianne A.J. Esselink, Rob M.A. de Bie, et al.
Movement Disorders (2021) Vol. 36, Iss. 6, pp. 1293-1307
Open Access | Times Cited: 29
F. Nijhuis, Rianne A.J. Esselink, Rob M.A. de Bie, et al.
Movement Disorders (2021) Vol. 36, Iss. 6, pp. 1293-1307
Open Access | Times Cited: 29
Current and novel infusion therapies for patients with Parkinson's disease
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1349-1358
Open Access | Times Cited: 12
Angelo Antonini, Valentina D’Onofrio, Andrea Guerra
Journal of Neural Transmission (2023) Vol. 130, Iss. 11, pp. 1349-1358
Open Access | Times Cited: 12
